311 In so far as, when it examined whether Clause 4 of the General Sales Conditions would or would not eliminate competition for a substantial part of the products, the Commission further stated, at recital 188 to the Decision, that, in any event, for several of the leading products affected by the General Sales Conditions, GSK held substantial market shares (for example, for Zofran, Flixonase, Zovirax and Imigran) in one or more Member States, it remains necessary to review that assessment.
Ryhmä II:n organisaatiot ovat tässä asiassa selkeästi aktiivisimpia (yli # prosenttia), ja seuraavana tulevat ryhmä III:n organisaatiot (noin # prosenttiaEurLex-2 EurLex-2